Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Sartorius Stedim Biotech (DIMN) Price & Analysis

DIMN Stock Chart & Stats

MX$4,468.62MX$0.00(0.00%)
At close: 4:00 PM EDT
No data to display
Day’s Range
MXN 4,468.62 - MXN 4,468.62
52-Week Range
MXN 4,468.62 - MXN 5,811.46
Previous Close
MXN 4,468.62
Volume
N/A
Average Volume (3M)
0
Market Cap
MXN 457.73B
Enterprise Value
MXN 22.86B
Total Cash (Recent Filing)
MXN 172.00M
Total Debt (Recent Filing)
MXN 2.31B
Price to Earnings (P/E)
66.9
Beta
-0.05
Next Earnings
Feb 23, 2027
EPS Estimate
30.86
Next Dividend Ex-Date
N/A
Dividend Yield
0.54%

Bulls Say, Bears Say

Bulls Say

Recurring Consumables And Installed Base

The mix of frequently replaced consumables and installed equipment creates repeat purchasing beyond one-time capital sales. As biopharmaceutical customers expand production, this model can support durable customer relationships, recurring revenue, and greater visibility across future manufacturing cycles.

Healthy Operating Margins

Gross and EBITDA margins remain healthy for the business, indicating meaningful value creation from its bioprocessing technologies, equipment, and consumables. These margins provide operating capacity to support research, product development, customer service, and growth investment over the next several quarters.

Improved Financial Stability

The substantial reduction in debt-to-equity strengthens the balance sheet relative to 2023 and improves financial flexibility. Higher equity and lower relative leverage should make it easier to fund operations and strategic investment while reducing the balance-sheet strain associated with prior debt levels.

Bears Say

Weak Cash Conversion

Positive operating and free cash flow are not converting efficiently from reported earnings, which reduces the quality and flexibility of profit generation. If this pattern persists, the company may have less internally generated cash available for investment, debt reduction, or shareholder returns.

Volatile Earnings Recovery

The recovery demonstrates improvement, but the multi-year earnings profile remains volatile and is still described as being in a rebuild phase. Performance below the 2022 peak means future results remain sensitive to the pace of biopharmaceutical production growth and customer capacity expansion.

Meaningful Debt And Moderate Returns

Although leverage has improved, the remaining debt burden is still material relative to the company’s current return profile. Moderate ROE suggests capital is not yet generating returns comparable with prior highs, limiting the strength of balance-sheet efficiency and leaving less room for execution setbacks.

Sartorius Stedim Biotech News

DIMN FAQ

What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was Mex$4468.62 and its highest was Mex$5811.46 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is Mex$457.73B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Feb 23, 2027 which is in 114 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Oct 22, 2026. The company reported Mex$24.772 earnings per share for the quarter, missing the consensus estimate of Mex$25.381 by -Mex$0.609.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech does not currently pay dividends.
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 30.86.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of Mex$24.772 in its last earnings report, missing expectations of Mex$25.381. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in MX:DIMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology